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Abstract
Background & Aims—Only a minority of heavy drinking individuals develop alcoholic 
hepatitis (AH), for unclear reasons. We analyzed data from the Translational Research and 
Evolving Alcoholic Hepatitis Treatment cohort: subjects who drink heavily with normal results 
from liver tests (controls) and patients with AH. We examined risk factors for the development of 
AH including body mass index (BMI), drinking pattern and quantity, and sex.
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Methods—We compared data from 145 patients with AH cases and 124 controls, based on BMI 
when they joined the cohort; groups were matched for sex and race. Drinking patterns were 
assessed using the time line follow back method, the Alcohol Use Disorders Identification Test, 
and National Institute of Alcohol Abuse and Alcoholism 6-question survey. We performed 
univariable and multivariable analyses we to assess effects of these factors and their interaction in 
increasing the risk for AH. We also explored the association between PNPLA3 variants and AH.
Results—Cases with AH were older (47 vs 44 years; P=.03). For nearly all measures of quantity 
of alcohol consumed or frequency of binge drinking, controls drank more heavily than cases with 
AH. We did not find an association between BMI, sex, drinking patterns, and the presence of AH. 
Age and BMI were independent predictors for severity of AH. When we analyzed cases and 
controls of European ancestry, the PNPLA3 single nucleotide polymorphism rs738409 was 
associated with risk for AH (odds ratio, 1.89; P=.007).
Conclusion—Compared with heavy drinkers without liver disease, subjects with AH consumed 
lower levels of alcohol and had less binge drinking, suggesting an increased sensitivity to the toxic 
effects of alcohol. The risk for AH may be associated with the PNPLA3 rs738409 polymorphism.
Keywords
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INTRODUCTION
Alcoholic liver disease (ALD) represents a spectrum of clinical illness and pathological 
change in individuals with acute and chronic alcohol consumption. Patients may have 
minimal abnormalities ranging from steatosis to more severe signs and symptoms of liver 
disease associated with inflammation and fibrosis seen in alcoholic hepatitis or cirrhosis1. 
Despite the fact that the relationship between alcohol consumption and liver disease is well 
established, severe alcohol-related morbidity and ALD only develop in a small minority of 
excessive drinkers1. This observation suggests that there are other factors that alter the risk 
of AH from excessive alcohol use. Delineation of such factors could lead to screening for 
ALD and institution of more intensive treatment for heavy drinking.
The quantity of alcohol consumed is a major factor placing one at risk for ALD. However, 
studies have shown that such risk may also depend on the patterns of alcohol intake, 
independently of the absolute levels of consumption. For instance, binge drinking (too much 
too fast) and chronic excessive drinking (too much too often) have been cited as significant 
determinants of risk for ALD2, 3. It is important to note that a precise study of the 
relationship between development of ALD and the quantity of alcohol consumed is almost 
unachievable, because data collection always involves different definitions and subjective 
estimates of alcohol consumption. The greater vulnerability of women and lower safe limits 
for alcohol consumption have long been recognized4. At any given level of alcohol intake, 
women had a significantly higher relative risk of developing ALD than men. However, in the 
Dionysos study, the risk for ALD for both sexes was comparable when the consumption 
exceeded 30 gram of alcohol/day3.
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Another modifiable risk factor for the development of ALD is body weight. In an 
epidemiological study from the US, overweight and obesity increased the risk of alcohol-
related abnormal alanine aminotransferase activity5. Another large study from France 
showed that the presence of excess weight for at least 10 years is a risk factor for AH and 
alcohol-associated cirrhosis6.
Alcoholic hepatitis (AH) is the most florid manifestation of ALD and is associated with high 
mortality7. The majority of patients with severe AH have fibrosis on biopsy at presentation, 
and approximately 10% to 20% of patients with AH are likely to progress to clinically 
obvious cirrhosis annually8. While quantity of alcohol consumption, gender, and body 
weight have been associated with the overall risk for ALD, less is known about the 
associations of these factors for AH specifically. The DIONYSOS study of patterns and 
types of beverages consumed combined steatosis and AH in the non-cirrhotic liver disease 
group without doing subgroup analysis3. Naveau et al., on the other hand, found that female 
gender and obesity were risk factors for AH; however, in the multivariable analysis, the 
amount of alcohol consumed did not correlate with the risk of AH6. Since the development 
of AH may be a common pathway to cirrhosis for many patients, confirmation of these 
results in an American population, and multivariable analysis of interactions between these 
various risk factors are of interest, particularly given the growing number of Americans who 
are overweight or obese.
The purpose of the present study was to examine the effect of drinking patterns, gender, 
body weight and their interactions on the risk for AH in a well-characterized cohort of 
subjects who were recruited by the Translational Research and Evolving Alcoholic hepatitis 
Treatment (TREAT) consortium.
METHODS
See full details in Supplementary material.
RESULTS
Demographic and clinical characteristics of the study cohort
The detailed characteristics of the study cohort are summarized in Table 1. Subjects with AH 
were older than controls (47 vs. 44 yr, p=0.03). Among AH cases, the majority of subjects 
were men (60%) and White (88%). There were no differences in the mean BMI between the 
groups; and the percentage of individuals with a BMI>25 was not significantly different 
(67% of cases vs 63% of the controls (p = 0.445). As expected from the inclusion criteria, 
the liver tests were worse in the cases than the controls, and the MELD scores higher. The 
cases had lower hemoglobin and platelet counts, and higher leukocyte counts; serum 
creatinine was slightly higher in the cases.
Quantity and patterns of alcohol consumption in controls and AH cases
The drinking patterns of the cases with AH and control subjects are shown in Table 2. Total 
drinks and average drinks per drinking day during the 30 days prior to recruitment and 
estimated drinks in the past year (assessed from the TLFB survey) were significantly lower 
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in cases compared to controls. Using a definition of binge drinking as more than 4 
drinks/day for men or more than 3 drinks for women, more of the controls were classified as 
binge drinkers. Using an episodic drinking score, the controls drank more episodically (they 
were more likely to drink larger amounts on fewer days) than the cases (more likely to drink 
on more days). Among subjects with AH, the episodic drinking score was higher in men 
than that in women (28 ± 43 vs. 15±18, p = 0.04). This was confirmed using AUDIT and 
NIAAA six question results: more control patients reported daily binge drinking, and more 
also reported weekly binge drinking than did the patients with AH. Total drinks in the past 
year calculated from the NIAAA questions were significantly higher for the controls than 
the cases. The results were similar to those calculated from the TLFB. Among subjects with 
AH, men had a higher estimated number of drinks in the past year based on NIAAA 
questions compared to women (3,200±2,520 vs. 2353±2273, p=0.04). One final measure 
was the maximum number of drinks ever consumed in one day: 50% of the controls and 
40% of the cases reported drinking more than 23 drinks in 24 hours (not significant).
When we stratified the alcohol consumption data by gender for the cases vs controls; we 
observed that the total alcohol consumption in the past 30 days (total drinks and average 
drinks per drinking day) was similar between men and women within the control and case 
groups. The episodic drinking score was higher in the women than the men in the case, but 
not control, group. There were no differences in the binge drinking measures between men 
or women within the control or case groups (Table 2). Men reported higher maximum drinks 
on a single occasion than women in both the controls and cases.
We also examined the differences in alcohol drinking quantity and pattern between men with 
and without AH, and women with and without AH (Table 2). For the men, the controls had 
higher total drinks and average drinks per drinking day, and a higher percentage of binge 
drinking daily than the men with AH. For women, the controls had higher total drinks and 
average drinks per day, higher episodic drinking scores, and higher binge drinking daily or 
weekly (NIAAA questions) than did the women with AH. There were no differences in 
maximum drinks on one occasion between men and women with and without AH.
Taken together, these data show that the patients with AH had less exposure to alcohol 
(quantity consumed), and were less likely to binge drink than the control patients, suggesting 
that the subjects with AH were more susceptible to the toxic effects of alcohol.
The association between the quantity and pattern of alcohol consumption and the effect of 
gender and BMI on AH
Previous studies have suggested that overweight or obese patients, and women, are at greater 
risk of developing AH6. We therefore examined the interactions between BMI and gender 
and either total alcohol consumption in the last 30 days (Table 3) or a history of binge 
drinking (Table 4) and the diagnosis of AH.
There was no association between total alcohol consumption in the past 30 days, BMI, and 
gender and increased risk for AH (Table 3), nor an interaction between these factors. The 
same results were found when we analyzed the association between pattern of drinking 
(using the NIAAA questionnaire reflecting daily binge drinking) and increased risk for AH 
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(Table 4). When compared to controls, heavier alcohol use and binge drinking were 
inversely associated with the presence of AH because of the higher levels of drinking 
observed in the control group than in the cases (Table 2). We did not find any interaction 
between BMI, gender, and binge drinking and the presence of AH.
The effect of age, gender, and BMI on the severity of AH
We next assessed interactions between age, gender, and BMI on the severity of AH, as 
indicated by MELD scores (Table 5). In the unadjusted linear regression model, we found 
that age was inversely associated with the MELD scores (β estimate −0.09, p = 0.0004). 
Women and subjects with higher BMI were likely to have more severe AH. However, in the 
adjusted model, only age (β estimate −0.18, p = 0.0005) and BMI (β estimate 0.31, p<0.001) 
were independent predictors for severity of AH. The interaction of gender and BMI was not 
statistically significant (p=0.06).
The association between PNPLA3 polymorphism and AH
Our data indicated that when compared to heavy drinkers without liver disease, the cases 
developed AH despite consuming less alcohol, suggesting they are more susceptible to the 
hepatotoxicity of alcohol, which could reflect a genetic susceptibility. A recent meta-
analysis showed that the rs738409 variant of PNPLA3 was associated with alcoholic liver 
cirrhosis13; however, the association between this PNPLA3 variant and AH has not been 
studied.
We focused our analyses on PNPLA3 polymorphism on those of European ancestry among 
124 controls and 145 cases with AH,. Ninety cases with AH and 93 controls met this 
criterion. The quantity and patterns of alcohol consumption among these subjects are shown 
in Supplementary material, Table S1. The overall Minor allele frequency (MAF) of PNPLA3 
rs738409 was 0.34 in cases, and 0.22 in controls (p = 0.007, OR 1.89 (95% CI 1.171 – 
3.056), Supplementary material, Table S2). The relationship between rs738409 genotype and 
age, gender and BMI was assessed, but none of the statistical tests (both parametric and non-
parametric) reached significance (Supplementary material, Table S3), suggesting that age, 
gender and BMI are not associated with rs738409 genotype.
DISCUSSION
The major findings in our study are the following: 1) the total amount of alcohol 
consumption in the last 30 days, and rates of binge drinking were significantly lower in 
cases with AH when compared to controls, 2) age was inversely associated with the severity 
of AH, 3) subjects with higher BMI had higher risk for severe AH, and 4) the rs738409 
variant of PNPLA3 may be associated with risk for AH, independently from age, gender, 
and BMI.
Information is limited on the effect of age, gender, body weight, and the quantity and 
frequency of alcohol consumption and the risk of AH, as several previous studies focused 
mainly on alcoholic cirrhosis14, 15. The risk for alcoholic cirrhosis in general is related to the 
quantity of alcohol consumed 14, 15. A meta-analysis found that consumption of more than 
25 g/day increased the relative risk of cirrhosis16; and that the threshold for harm is lower 
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for women17, 18. In addition to drinking frequency, episodic or binge drinking has been 
associated with an increased risk of alcoholic cirrhosis19, 20. Although alcohol itself is an 
important risk factor for ALD, as previously observed by numerous groups, and conclusively 
proven by Lieber in his baboon feeding experiments21, only a subset of subjects who 
consume alcohol excessively develop liver disease; suggesting that other risk factors besides 
the amount of alcohol must be important for alcohol-associated liver disease1.
Our study is perhaps the first to examine the various measures of alcohol use (quantity, 
frequency of binge drinking) between heavy drinking patients with normal liver tests and 
heavy drinking patients with alcoholic hepatitis, using validated questionnaires to quantify 
these measures. All of the patients in our cohorts drank more than the thresholds for 
alcoholic liver disease cited above, and most were drinking at a level which confounds the 
determination of binge drinking. The notion of binge drinking as a risk for alcoholism and 
liver injury is based on the definition of more than 3 or 4 drinks within a two hour period, a 
level of drinking expected to raise the blood alcohol level to 80 mg/dL or more. This is the 
measure assessed in the NIAAA six question survey. Since nearly all of the control patients 
reported binge drinking nearly daily or weekly, as did 75% of the cases, this formal 
definition of binge drinking does not discriminate between those with and without liver 
injury, nor did it appear to contribute to severity of the AH. This may simply be a reflection 
of the very high levels of drinking we observed in both groups: the average drinks per 
drinking day exceeded the threshold for binge drinking by about two-fold. In a similar vein, 
measures of total alcohol consumption in the last month or year did not predict the 
occurrence of AH. While we did not collect information about the age of onset of heavy 
drinking, the fact that the AH cases were only slightly older than the controls suggests that 
total duration of drinking is not a strong determinant of the development of AH. Further, our 
data suggest that beyond a threshold of heavy drinking, there is not a direct relationship 
between amount or pattern of drinking and the occurrence of AH. This is consistent with the 
data reported by Naveau et al. when they compared alcohol consumption between heavy 
drinkers with normal liver biopsies and those with pure (i.e., not cirrhotic) AH6. We note 
that our control patients reported drinking approximately 50% more alcohol (converting the 
drinks per month to grams of absolute alcohol per day) than the French patients with normal 
histology, while our patients with AH drank at nearly the same level. The fact that the 
subjects with AH were drinking less than the controls points to some other factors in 
addition to alcohol per se that predisposed them to liver injury.
We examined three other potential risk factors which had previously been suggested to 
contribute to AH risk, age, gender, and BMI, and looked for interactions with measures of 
alcohol consumption. We found that age at presentation is inversely associated with the 
severity of AH, as measured by MELD scores, i.e. that older patients are likely to present 
with less severe AH. Our findings are consistent with a previous report which showed that 
younger people are at higher risk to develop AH22, 23. The reason behind this observation is 
unclear, but might be consistent with the development of AH in patients with a genetic 
predisposition (however, we did not see an association of the PNPLA3 risk allele and age of 
diagnosis). On the other hand, a recent study reported that older age at onset of heavy 
drinking (after age 24), was associated with increased risk of developing cirrhosis (alcoholic 
hepatitis was not studied), with shorter duration of heavy drinking, lower daily alcohol 
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consumption, and worse Child-Pugh score at diagnosis24. A possible explanation is that 
there is a greater risk of developing AH as well as cirrhosis in those who begin drinking 
heavily after age 24, with more rapid progression and presentation with more severe disease; 
this would have been observed in our cohort as less severity in those presenting at an older 
age. Women tend to develop higher blood alcohol concentrations per unit of alcohol 
consumed due to their lower volume of distribution for alcohol4. High levels of estrogen in 
women may cause alterations in gut permeability to endotoxin and accordingly up-regulate 
endotoxin receptors on Kupffer cells, leading to an increased production of tumor necrosis 
factor in response to endotoxin and the risk of ALD25, and higher BMI in women is 
expected to be associated with elevated levels of estradiol (generated, particularly after 
menopause from the conversion of androgens to estrogen in the adipose tissue)26. In our 
study, we found that women are at greater risk for severe AH; however, the association 
disappeared after controlling for other covariates. Naveau et al,6 reported that obesity 
increased the risk of AH without cirrhosis. We found that BMI is an independent predictor 
for severe AH (and our inclusion criteria included patients with AH superimposed on 
cirrhosis). Increasing body weight may predispose patients to hepatotoxicity of alcohol 
because of the inflammatory nature of obesity, a greater degree of steatosis, or other factors.
PNPLA3 gene is located on the long arm of chromosome 22 and codes for the protein 
adiponutrin27. Tian et al. found a significant association between PNPLA3 rs738409 and 
alcoholic cirrhosis and the results were confirmed in a German cohort28 and the study by 
Buch et al29. PNPLA3 rs738409 (G/G) carriers represent a genetically defined 
subpopulation of high-risk patients susceptible to progression from clinically-silent to overt 
ALD. Interestingly, our preliminary results also show the association between this variant 
and the risk for AH. We are currently investigating this finding, and other possible leads to 
genetic predisposition to AH, in more detail.
The strengths of this study are the prospective design, inclusion of well characterized heavy 
drinking control group, the extensive assessment of drinking behavior, and its large sample 
size. A limitation common to all studies of long term alcohol consumption is the validity of 
self-reported drinking. We attempted to overcome this by using three different 
questionnaires to assess the quantity as well as pattern of drinking. We also considered the 
quantity of drinking over the past year, based on the fact that many patients with AH may 
have reduced or stopped alcohol within the weeks preceding the episode of AH. Regardless 
of the methods to determine the levels as well as drinking pattern, we found that subjects 
with AH were drinking less than the controls. The important conclusion is that beyond a 
certain level of heavy drinking, the amount of alcohol consumed does not appear to be a 
specific risk factor for development of AH. Further, our alcohol consumption data are cross 
sectional and we have no way of knowing what the total exposure to alcohol was in either 
group. Other limitations include the impracticality of performing a liver biopsy on all 
patients, and the ethical impossibility to perform biopsy in controls, to be certain of the 
diagnosis. It is possible that our subjects could have any degree of liver disease from no 
fibrosis to cirrhosis. The use of non-invasive tool such as ultrasound has high specificity for 
cirrhosis; however, its low sensitivity prohibits its use as a screening modality30. In future 
studies, Fibroscan might be useful in further characterizing the controls and cases, 
recognizing the effect of heavy drinking per se on the liver stiffness measurement. It is worth 
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noting that none of the control patients developed clinical liver disease in the year of follow 
up. Understanding the baseline hepatic pathology is of importance, as it is possible that 
development of fibrosis or cirrhosis indeed predisposes the patient to the development of 
AH. Alternatively, sub-clinical AH may be a precursor to fibrosis and cirrhosis. These 
hypotheses cannot be directly tested due to the cross sectional study design of our study.
In conclusion, we found that when compared to heavy drinkers without liver disease, 
subjects with AH had lower levels of alcohol consumption and less binge drinking. Younger 
subjects, and those with high BMI are at risk for more severe AH at presentation. The risk 
for AH appears to be associated with the presence of PNPLA3 polymorphism.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Baseline demographic and clinical characteristics of the study cohort
Variables Controls (N=124) AH cases (N=145) p-value
Age (years) 44 ± 12 47 ± 11 0.03
Men, n (%) 78 (63) 87 (60) 0.62
Race, White, n (%) 103 (83%) 128 (88%) 0.22
BMI (kg/m2) 28.7±7.1 29.4±7.6 0.44
WBC (cells/mm3) 7.1 ±2.8 11.6±8.2 <0.0001
Hemoglobin (g/dl) 13.0±2.1 10.0±1.9 <0.0001
Platelet counts (cells/mm3) 245±72 145±87 <0.0001
T. Bilirubin (mg/dL) 0.5±0.3 13.7±11.6 <0.0001
INR 1.0±0.3 1.8 ±0.5 <0.0001
AST (U/L) 27±9 140±87 0.0001
ALT (U/L) 26±10 64±7 0.0001
Albumin (g/dL) 3.8±0.6 2.8±0.6 <0.0001
Creatinine (mg/dL) 0.8±0.3 1.0±0.8 0.05
MELD Scores 7.2±2.2 22.1±7.1 <0.0001
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Table 3
Multivariable analysis of the effect of total alcohol consumption in the past 30 days, gender and BMI on 
alcoholic hepatitis
Parameters Odds Ratio (95%CI) p-value p-value for total drinks 
and gender interaction
p-value for total drinks 
and BMI interaction
Age 1.01 (0.99–1.04) 0.16 - -
Race (white vs. Non-White) 1.53 (0.74–3.15) 0.24 - -
Total drinks in the past 30 days (standard drinks) 0.99 (0.99–0.99) 0.003 - -
Gender (Men vs. Women) 0.89 (0.53–1.50) 0.66 - -
BMI 1.01 (0.97–1.04) 0.61 - -
Total drinks in the past 30 days (standard 
drinks)*Gender
- - 0.95 -
Total drinks in the past 30 days (standard 
drinks)*BMI
- - - 0.77
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Table 4
Multivariable analysis of the effect of binge drinking, gender and BMI on alcoholic hepatitis
Parameters Odds Ratio (95%CI) p-value p-value for binge drinking and 
gender interaction
p-value for binge drinking and 
BMI interaction
Age 1.02 (0.99–1.04) 0.07 - -
Race (white vs. Non-White) 1.48 (0.70–3.14) 0.30 - -
Binge drinking 0.13 (0.04–0.39) 0.0003 - -
Gender (Men vs. Women) 0.97 (0.56–1.65) 0.91 - -
BMI 1.02 (0.98–1.05) 0.34 - -
Binge drinking*Gender - - 0.95 -
Binge drinking*BMI - - - 0.62
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